Heron Therapeutics
HRTX
124 hedge funds and large institutions have $1.25B invested in Heron Therapeutics in 2017 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 29 reducing their positions, and 9 closing their positions.
330% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $3.32M
222% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 9
66% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 29
22% more capital invested
Capital invested by funds: $1.02B → $1.25B (+$224M)
19% more funds holding
Funds holding: 104 → 124 (+20)
9.97% less ownership
Funds ownership: 117.12% → 107.15% (-10%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$22.9M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$21.1M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$9.22M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.96M |
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$23.3M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
-$7.69M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.03M |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.33M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$4.58M |
HRTX Hedge Fund Activity: Q4 2017 in Review
124 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2017, worth a combined $1.25B — up 22% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new HRTX positions and 9 closed out — a net gain of 20 holders — while 48 added to existing stakes and 29 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $24.6M. The largest seller was Broadfin Capital, cutting an estimated $23.3M.
- 124 institutional investors held Heron Therapeutics (HRTX) as of Q4 2017, up from 104 in Q3 2017.
- Funds reported $1.25B of Heron Therapeutics stock for Q4 2017, up 22% quarter-over-quarter.
- 29 funds opened new Heron Therapeutics positions in Q4 2017 and 9 closed out, a net change of +20 holders.
- The largest Heron Therapeutics buyer in Q4 2017 was Fidelity Investments, an estimated $24.6M added.
- The largest Heron Therapeutics seller in Q4 2017 was Broadfin Capital, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2017.